Con esta herramienta te facilitamos un acceso a todas las ofertas y demandas de tecnología europeas y a búsquedas de socios para participar en propuestas europeas de I+D publicadas en la red Enterprise Europe Network, pudiendo filtrar los resultados para facilitar las búsquedas más acordes con tus necesidades.

¿Quieres recibir estos listados de oportunidades de colaboración en tu correo de forma periódica y personalizada? Date de alta en nuestro Boletín

Para optimizar los resultados de la búsqueda, se recomienda utilizar términos en inglés.

Plataforma para restaurar la tolerancia en pacientes alérgicos

Resumen

Tipo:
Oferta Tecnológica
Referencia:
TONL20151209003
Publicado:
24/02/2016
Caducidad:
24/02/2017
Resumen:
Una pyme holandesa ha desarrollado una plataforma para reducir activamente la inflamación inmune no deseada que se aplica para restaurar la tolerancia en pacientes alérgicos. Esto se consigue a través de la inducción de células T reguladoras mediante la modificación de glicanos de alérgenos o péptidos derivados de estos alérgenos. La tecnología se basa en la glicosilación de antígenos a los que se dirige la respuesta inmune. La empresa busca compañías del sector de biotecnología especializadas en investigación y desarrollo en el campo de alergias y tratamiento de alergias alimentarias para continuar con el desarrollo de la tecnología y establecer acuerdos de cooperación en materia de investigación.

Details

Tittle:
Platform technology to restore tolerance in allergic patients
Summary:
A Dutch SME has developed a platform technology that enables to actively dampen unwanted immune inflammation and can be applied to restore tolerance in allergic patients. The company is looking for life science companies actively involved in allergy research and development and food allergy treatment for further development of this technology in the framework of research cooperation.
Description:
Antigen specific immunotherapeutics and -vaccines are considered as one of the most promising new developments in the search to induce tolerance in allergy patients. These therapies rehabilitate the immune system and prepare the human body to fight the disease. The main challenge in developing effective antigen-based immunotherapeutics is to efficiently target and trigger dendritic cells (DCs) in order to elicit a specific, potent, and long term immune response without adverse effects. Only then these types of treatments can be successfully applied in a clinical setting.

The Dutch SME has developed a novel targeting approach that has the potential to develop effective antigen-based immunotherapeutics. It discovered that some DC receptors have a high specificity for binding specific glycan structures and has demonstrated in several national and international research projects that glycan structures can be used as probes to directly target DCs in tissue and thereby trigger and modulate a specific immune response.

The core of the proprietary technology is glycation of antigens to which the immune response is directed. Glycans are complex carbohydrate structures that form recognition elements for glycan-specific receptors that, upon recognition, mediate cellular communication.

This targeting technology can be applied to restore tolerance in allergic patients. This can be achieved via induction of regulatory T-cells by glycan-modification of allergens or peptides derived from these allergens. Additionally, DCs targeted with the glycan-modified allergens may inhibit established allergen-specific T-cells directly. Glycan-conjugated disease-specific allergens may be used for effective treatment of different types of food allergies including peanut- and cow´s milk allergy.

To exploit the potential for the targeting technology in the development of anti-allergy products the company is looking for life science companies actively involved in allergy research and development. Cooperation in European projects like Horizon 2020 or Eurostars is offered.
Advantages and Innovations:
The immuno-therapeutics that can be developed using this technology, are exceptional because they are potent, tailor made (trigger and modulate a specific immune response), durable (tolerance can be restored in allergic patients) and applicable to any type of antigen or vehicle.
Stage of Development:
Under development/lab tested
IPs:
Patents granted
CommeR Statunts Regarding IPR Status:
Patents for tolerance induction granted in US and pending in Europe, Japan, China, Canada and Australia.

Partner sought

Type and Role of Partner Sought:
Partners this company is looking for are companies and researchers in life sciences in the food industry. The partners should be active in allergy research and development and food allergy treatment including peanut- and cow´s milk allergy.

Cooperation offered is co-development of the technology in the framework of research cooperation.

Client

Type and Size of Client:
Industry SME <= 10
Already Engaged in Trans-National Cooperation:
Si
Languages Spoken:
Dutch
English
French
German

Keywords

Technology Keywords:
08001005 Tecnología de alimentos
06001006 Vacunas humanas